Interferon-gamma (IFN-g) exhibits biological activities that are considered to have important roles in tumor suppression. Therefore, the IFN-g gene is a potential candidate for in vivo cytokine gene therapy against skin cancer. The present study evaluated the efficacy of a hydrodynamics-based IFN-g gene transfection for skin cancer treatment, in which the plasmid DNA encoding IFN-g was administered into the tail vein of mice following 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetateinduced skin carcinogenesis. Serum levels of IFN-g were substantially elevated without liver toxicity. The mice injected with IFN-g plasmid DNA displayed a marked reduction in papilloma numbers, suppressed proliferation of epidermal cells and induction of caspase-3-mediated apoptosis. These results suggest that the hydrodynamics-based transfection of IFN-g plasmid DNA is a convenient and efficient means of skin cancer gene therapy.
Introduction
Skin cancer is the most common type of cancer that is associated with exposure to solar radiation, which is a major public health concern.
1 Various skin cancer treatments have been used including surgery, radiotherapy, chemotherapy and gene therapy. 2 The latter has assumed greater prominence due to developments in molecular genetics, immunology, cellular biology and tumor biology. 3 Interferon-gamma (IFN-g) has various biological effects in both host defense and immune regulation, including antiviral activity and antimicrobial activity. IFN-g efficacy in the clinical treatment of various cancers has also been reported, which has prompted the development and testing of IFN-g-based cancer gene therapy. [4] [5] [6] Delivery of the therapeutic genes to target sites in gene therapy has been explored using several approaches. One approach, which utilizes an intravascular injection of naked plasmid DNA encoding cytokine gene, has attracted attention lately as a novel method of controlling the in vivo pharmacokinetics of naked plasmid DNA. 7 A high level of transgene expression can be readily obtained in the liver and other major organs by a simple intravenous high-speed injection in the tail vein of mice of naked plasmid DNA in a large volume of saline, the so-called hydrodynamics-based procedure. 8, 9 It is very useful compared with other gene delivery systems in terms of efficiency, simplicity and productivity. 10 Therefore, the hydrodynamics-based procedure is expected to become the key gene delivery methodology for in vivo gene therapy.
In this study, we evaluated the anticancer effects of IFN-g plasmid DNA with the hydrodynamics-based procedure in a mouse skin carcinogenesis model, to assess the possibility of its application in skin cancer gene therapy.
Materials and methods

Molecular cloning of mouse IFN-g (mIFN-g)
Total RNA was extracted from mouse spleen cells using the RNeasy Mini kit (Qiagen, Valencia, CA) and cDNA was synthesized from the extracted RNA using random hexamers (Invitrogen, Carlsbad, CA) and SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions. The primer sequences for the amplification of mIFN-g were: forward primer, 5 0 -ATGAACGCTACA CACTGCATC-3 0 , and reverse primer, 5 0 -TCAGCAGCG ATCCCTTTTCC-3 0 (Genbank accession numberK00083). The cDNA was amplified by polymerase chain reaction (PCR) using HiPi PCR Premix (Elpisbio, Taejeon, Korea) with 5 pmol of the primers. PCR conditions were: initial denaturation at 95 1C, followed by 35 cycles of 95 1C for 1 min, 60 1C for 1 min, and 72 1C for 1 min. A final elongation step was carried out at 72 1C for 10 min. The expected size of the mIFN-g PCR product was 468 bp. The PCR products were separated in a 0.7% agarose gel, visualized with ethidium bromide and purified using the QIAquick gel extraction kit (Qiagen).
PCR products were cloned into a pGEM-T Easy vector (Promega, Madison, WI). The IFN-g gene fragment from the vector was cloned into the NotI restriction endonuclease (New England Biolabs, Ipswich, MA) site of the expression vector, pcDNA 3.1( þ ) (Invitrogen). The recombinant plasmid sequence was confirmed by sequence analysis and was designated pcDNA3.1-mIFN-g. The sequence was purified using a QIAprep Miniprep kit (Qiagen), dissolved in 0.9% normal saline to a concentration of 100 mg ml À1 and stored at À20 1C until used.
Evaluation of mIFN-g recombinant protein expression
Vero cells (CRL-1587; American Type Culture Collection, Manassas, VA) were prepared to a concentration of 2-6 Â 10 4 cells per ml, using an antibiotic-free growth medium. Aliquots of 2 ml of the cell suspension were added to wells of a 6-well plate and incubated at 37 1C in a 5% CO 2 atmosphere until the cells attained 50-80% confluent growth. The Vero cells were transfected with the pcDNA3.1-mIFN-g using Lipofectamine reagent (Invitrogen) according to the manufacturer's instructions. The supernatants were collected and stored for mIFN-g cytokine quantification of the recombinant protein on day 3 after passage. Cytokine expression in 100 ml of the supernatant from each well was measured using an mIFN-g ELISA kit (R&D Systems, Minneapolis, MN).
Measurement of serum IFN-g level and liver toxicity in mice after tail vein injection of IFN-g plasmid Six-week-old, female BALB/c mice were randomly divided into four groups (n ¼ 5 mice in each group). Mice in the control group were injected with 0.9% normal saline (1.6 ml). Mice in the three IFN-g groups were each injected with 1.6 ml of normal saline containing 10, 20 or 30 mg of pcDNA3.1-mIFN-g. Each injection was completed within 5 s. One day post-injection, to confirm the expression of IFN-g in the mice, blood was collected and serum was obtained by centrifugation at 2000 g for 20 min. The serum samples were assayed for IFN-g level using a mIFN-g ELISA kit (R&D Systems). For estimation of liver toxicity, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured using a Metrolab 2300 Plus V4 apparatus (Metrolab SA, Geneva, Switzerland).
Mouse skin carcinogenesis model
Six-week-old, female BALB/c mice were randomized into two groups (n ¼ 8 mice per group) and acclimated for 1 week. The back of each mouse was shaved 2 days before the start of the experiment. Each mouse received two topical applications of 25 mg of 7,12-dimethylbenz[a]anthracene (DMBA) in 100 ml of acetone at an interval of 72 h, followed by applications of 100 ml acetone containing 4 mg of 12-O-tetradecanoylphorbol-13-acetate (TPA) twice a week for 16 weeks. IFN-g plasmid DNA treatment was initiated at week 11. The control group of mice was injected with 20 mg of pcDNA3.1 in 1.6 ml saline as a vehicle vector via the tail vein. The IFN-g group of mice was injected in the tail vein with 20 mg of pcDNA3.1-mIFN-g in 1.6 ml saline. Each group of mice was injected twice a week until the conclusion of the experiment.
Detection of papilloma in the mouse skin carcinogenesis model Mice in each of the aforementioned groups were carefully examined twice weekly to detect papilloma. The method of detection of papilloma was standardized in our laboratory and skin papillomas with a diameter 41 mm that persisted for at least two consecutive observations were used for counting. Papillomas that regressed after one observation were not considered for counting. Two different experts who were not associated with the research team conducted all enumerations.
Measurement of serum IFN-g level and liver toxicity induced by pcDNA3.1-mIFN-g in the mouse skin carcinogenesis model Blood was collected at the end of the experiment. Serum samples were assayed by mIFN-g ELISA according to the manufacturer's instructions. Serum ALT and AST values were measured by serum biochemistry.
Measurement of epidermal thickness
Mice were killed at week 17, and the dorsal shaved areas of the skin were sliced into several parts and washed in phosphate buffered saline. The tissue slices were fixed with 10% buffered formalin and embedded in paraffin. Tissue sections 4 mm in thickness were cut and stained with hematoxylin and eosin. Epidermal hyperplasia was determined as the mean vertical epidermal thickness of 10 locations by microscopic examination of skin tissue sections.
Detection of in situ cell proliferation Cell proliferation in mouse skin was measured using a proliferating cell nuclear antigen (PCNA) staining kit (Invitrogen) according to the manufacturer's instructions. Deparaffinized tissue sections were incubated with biotinylated mouse PCNA primary antibody at room temperature for 1 h and then incubated with horseradish peroxidase-conjugated streptavidin at room temperature for 30 min. The PCNA positive cells were visualized using 3,3 0 -diaminobenzidine substrate solution and other cells were counterstained with hematoxylin. Sections from skin were used for counting the labeled and unlabeled cells. The proliferative index was determined by dividing the number of PCNA positive cells by the total cells counted, and multiplying by 100.
Detection of in situ cell death (apoptosis) Apoptotic cells in skin were visualized by an established standard terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate -nick end labeling (TUNEL) method, using an in situ peroxidase-based cell death detection kit (Roche, Penzberg, Germany). Deparaffinized tissue sections were permeabilized using Triton X-100 (Sigma-Aldrich, St Louis, MO). The sections were then incubated with a TUNEL reaction mixture containing the terminal deoxynucleotidyl transferase and fluoresceindeoxyuridine triphosphate, at 37 1C for 1 h. Peroxidase was added and the slides were incubated at 37 1C for 30 min. 3,3
0 -Diaminobenzidine-substrate solution was added for 5 min, and each slide was counterstained with hematoxylin for 1 min, dehydrated and a coverslip was placed on top. Finally, the slides were washed and analyzed by light microscopy as described above. Sections of the skin were used for counting labeled and unlabeled nuclei in cells. The apoptotic index was determined as the percentage of labeled nuclei with respect to the total number of nuclei counted.
Detection of caspase-3 activity in the skin cytosol Caspase-3 activity in skin was measured using a Caspase-3 Colorimetric Activity Assay Kit (Millipore, Billerica, MA) according to the manufacturer's instructions. In brief, all mice were killed at the end of the experiment. Skin samples were obtained by incision. Cytosolic extracts were prepared by homogenization of skin tissues in extraction buffer containing 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.5), 5 mM MgCl, 1 mM ethylene diamine tetraacetic acid, 0.1% (w/v) 3-[(3-cholamidopropyl)dimethylammoni]-1-propanesulfonate and 10 mg ml À1 aprotinin. Subsequently, the homogenates were centrifuged at 10 000 g for 5 min at 4 1C. The supernatant fraction was used to determine caspase-3 activity, which was ascertained by a colorimetric assay conducted in a microplate. In the assay, cytosolic extract containing about 1 mg ml À1 protein was incubated for 1 h at 37 1C, with 90 ml of substrate buffer containing 100 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.5), 10% sucrose, 0.1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, 5 mM dithiothreitol and 10 ml of caspase-3 substrate (Ac-DEVDpNA (N-acetyl-Asp-Glu-Val-Asp-p-nitroanilide)). The amount of the p-NA chromophore released by caspase-3 was quantified by measuring the optical density at 405 nm. The caspase-3 activity was calculated using serially diluted standards (p-NA) and expressed as mM p-NA h À1 mg À1 of protein.
Statistical analyses
The data are expressed as mean±s.d. The means of the different parameters were compared between groups by analysis of variance and Student's t-test. Significant differences between the groups were evaluated using Minitab Statistical Software 13.20 (Minitab, State College, PA). Po0.05 was considered as the level of significance.
Results
Molecular cloning of mIFN-g
The mIFN-g gene was cloned into the expression vector pcDNA3.l ( þ ) to generate pcDNA3.1-mIFN-g. To verify the cloning of the mIFN-g gene, pcDNA3.1-mIFN-g was digested by the NotI restriction enzyme; two restricted fragments of pcDNA3.1 (5428 bp) and mIFN-g insert (468 bp) were revealed by electrophoresis (Figure 1a) . The sequence of the recombinant plasmid was confirmed by sequence analysis (data not shown).
Evaluation of mIFN-g recombinant protein expression
The recombinant IFN-g expression was estimated by measuring the IFN-g concentration in the supernatant of the transfected and non-transfected Vero cells by ELISA.
There was a significant difference in the recombinant IFN-g protein concentration between the supernatant of non-transfected Vero cells (not detected) and transfected Vero cells (227.4 ± 14.7 pg ml
À1
; Po0.001; Figure 1b ).
Serum IFN-g, ALT and AST levels in mice after tail vein injection of IFN-g plasmid DNA After a single injection of pcDNA3.1-mIFN-g, serum IFN-g levels of mice were increased significantly in the 10 mg group (Po0.01), and in the 20 and 30 mg groups (Po0.001), compared with the control (0 mg) group (Figure 2a) . These results demonstrated that intravenous injection of pcDNA3.1-mIFN-g induced high levels of IFN-g in the systemic circulation. The potential toxic effects of the procedure on mice were assessed by measuring the concentration of the liver-specific enzymes ALT and AST. No significant differences in serum ALT and AST levels were evident in any group (Figures 2b and c) .
Anti-tumor effect of pcDNA3.1-mIFN-g on the mouse skin carcinogenesis model To evaluate the anti-tumor properties of pcDNA3.1-mIFN-g, plasmid DNA was injected into the mice. Papilloma development began at week 6 and papilloma numbers were elevated similarly in both groups to week 11. Following injections of pcDNA3.1-mIFN-g from week 11, the numbers of papilloma in the IFN-g group of mice decreased at week 12. However, papilloma numbers of the control group injected with empty plasmid vector (pcDNA3.1) were not decreased. Differences of papilloma numbers between the IFN-g group and the control group reached statistical significance after week 13 (Po0.01; Figure 3a) . At the termination of the Serum IFN-g, ALT and AST levels in the mouse skin carcinogenesis model At the end of the experiment at week 17, serum IFN-g, ALT and AST levels were measured. After repeated injection of pcDNA3.1-mIFN-g, serum IFN-g levels increased significantly (Po0.001), compared with the control group mice injected with pcDNA3.1 (Figure 4a) . Also, there were no marked differences in serum ALT and AST levels between control and IFN-g groups of mice after multiple tail vein injection (Figures 4b  and c) .
Effects of pcDNA3.1-mIFN-g on epidermal hyperplasia
Vertical epidermal thickness of the skin was measured to assess effects of pcDNA3.1-mIFN-g on epidermal hyperplasia. The vertical epidermal thickness of the skin was 43.8±10.6 in the control group mice, but was reduced significantly (Po0.001) in the IFN-g group mice (23.8 ± 8.3; Figure 5 ).
Effects of pcDNA3.1-mIFN-g on cell proliferation
Cell proliferation of the skin was measured by PCNA immunohistochemistry at week 17 to confirm that pcDNA3.1-mIFN-g could reduce cell proliferation in the mice with skin carcinogenesis. Differences in the number of proliferative (PCNA positive) cells in the IFN-g group compared with the control group were observed (Figures 6a and b) . The proliferative index of the IFN-g group (37.5 ± 6.1) was reduced significantly (Po0.001) compared with the proliferative index of the control group of mice (54.2 ± 7.1; Figure 6c ).
Effects of pcDNA3.1-mIFN-g on apoptosis
Apoptosis that indicates the level of programmed cell death in the skin tissue was determined by a TUNEL assay. TUNEL-positive cells present in sections from skin tissues were enumerated (Figures 7a and b) . The apoptotic index was increased almost two-fold (Po0.01) in the IFN-g group (15.3±4.6) compared with the control group (8.6 ± 3.3; Figure 7c ).
Caspase-3 activity in the skin cytosol
The levels of caspase-3 activity in skin cytosol taken from all mice were analyzed to investigate further the molecular mechanisms behind the inhibitory effects of pcDNA3.1-mIFN-g on the mice with skin carcinogenesis. The levels of caspase-3 activity were found to be elevated when injected with the pcDNA3.1-mIFN-g during the carcinogenesis process. Caspase-3 activity was significantly (Po0.05) increased in the skin of the IFN-g group (36.5±15.2 mM p-NA h À1 mg À1 of tissue) in comparison with the control group (17.2 ± 12.1 mM p-NA h À1 mg À1 of tissue; Figure 8 ).
Discussion
In the present study, the efficacy of the hydrodynamicsbased procedure was examined as an alternative gene delivery method for cancer gene therapy. This procedure is very attractive compared with conventional plasmid DNA-carrier systems in terms of efficiency, simplicity and productivity. 11 Selective and significant level of transgene expression can be achieved by an intravenous injection of naked plasmid DNA solution without any additional compounds such as cationic liposomes or polymers. 10 The mechanism of plasmid DNA leading to efficient transgene expression is debatable. It has been proposed that naked plasmid DNA is taken up by hepatocytes through a receptor-mediated process after the extravasation provoked by the high pressure involved in the hydrodynamics-based procedure. 12 On the other hand, the hepatic uptake of naked plasmid DNA by this procedure appears to be a nonspecific event through cellular membrane-enhanced permeability. 13 After injection of IFN-g plasmid DNA into the tail vein, the transgene was expressed and detected in the circulation (Figures 2a and 4a) . The serum IFN-g levels of the 20 and 30 mg groups were statistically higher than those of the 10 mg group. Therefore, the plasmid DNA dose of 20 mg was selected for use, and the plasmid DNA injection was carried out twice weekly to the end of the experiment, to sustain the transgene expression at a high level, thereby enhancing the effect as much as possible. In the present carcinogenesis experiment, multiple injections of IFN-g expressing plasmid DNA resulted in profound reduction of skin papilloma numbers (Figures 3a-c) . As the injection of pcDNA3.1 as a control plasmid DNA showed no therapeutic effects, IFN-g expressed in a transgenespecific fashion was responsible for the observed tumor suppression. There was an anti-tumor effect against subcutaneous tumor by intratumoral injection of IFN-g expressing plasmid DNA.
14 However, no significant therapeutic effect was observed by the intravenous injection of IFN-g plasmid DNA on the subcutaneous tumors. 10 Differences in the nature of the tumor models or the injection schedules might account partly for the discrepancy in the therapeutic effects against tumor.
One of the most common events after topical application of DMBA-TPA on the mouse skin is a hyperproliferative response, such as epidermal hyperplasia and PCNA positive cells in epidermis, mediated by inflammatory responses. 1, 15 The measurement of proliferating activity has been used to determine the grade of precancerous lesions during carcinogenesis. 16 Throughout the present carcinogenesis experiment, tail vein injection of IFN-g plasmid DNA resulted in marked inhibition of epidermal hyperplasia and PCNA positive cells (Figures 5 and 6 ). These results indicate that the suppression of epidermal proliferation is due to the protective effect of IFN-g against skin carcinogenesis. Similar suppressions of cell proliferation by IFN-g have been shown in ovarian cancer and pancreatic carcinoma cells. 17, 18 IFN-g has been demonstrated to be a potent inducer of signal transducer and activator of transcription-1 activity, which subsequently induces transcription of interferon regulatory factor-1, promoting caspase-8 activity. 19, 20 Caspase-8 is an initiator caspase and is closely coupled to pro-apoptotic signals. Once activated, caspase-8 cleaves and activates downstream effector caspases, particularly caspase-3. Caspase-3 executes apoptosis by cleaving cellular proteins and inhibits cellular proliferation. 4, 21 In the present study, apoptotic index was significantly increased by injection of IFN-g plasmid DNA (Figure 7 ). Skin caspase-3 activity of the IFN-g group was increased, compared with that of control group (Figure 8 ). From these results, it can be inferred that caspase-3 activity is very important for causing apoptosis in mouse skin by injection of IFN-g plasmid DNA. The presently observed caspase-3-mediated apoptosis is similar with the findings of earlier studies that used recombinant IFN-g. 22, 23 Although recombinant IFN-g decreases cell proliferation and induces apoptosis, clinical trials are hampered by the short half life of the molecule in serum, its high cost and side effects. 20, 24 In the present study, however, hydrodynamics-based transfection of IFN-g plasmid DNA overcame these problems. Moreover, the anticancer effects were not accompanied by liver toxicity, as evident by a lack of increase in the serum concentration of ALT and AST.
In conclusion, taking advantage of the hydrodynamicsbased procedure, this study has demonstrated that tail vein injection of IFN-g plasmid DNA inhibited skin carcinogenesis by suppression of epidermal proliferation and induction of caspase-3 mediated apoptosis. Although some papillomas remained after treatment, this study supports the possibility that intravenous injection of IFN-g plasmid DNA has significant potential as an efficient therapeutic modality for systemic gene therapy against skin cancer.
